Your browser is no longer supported. Please, upgrade your browser.
EOLS Evolus, Inc. daily Stock Chart
Evolus, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own56.40% Shs Outstand26.90M Perf Week-1.24%
Market Cap429.86M Forward P/E- EPS next Y-3.04 Insider Trans- Shs Float11.86M Perf Month29.60%
Income-26.80M PEG- EPS next Q-0.59 Inst Own24.60% Short Float15.73% Perf Quarter10.82%
Sales- P/S- EPS this Y93.70% Inst Trans0.06% Short Ratio5.43 Perf Half Y-19.09%
Book/sh3.83 P/B4.17 EPS next Y-43.40% ROA-20.50% Target Price30.50 Perf Year-
Cash/sh3.91 P/C4.09 EPS next 5Y- ROE-109.70% 52W Range6.75 - 39.50 Perf YTD34.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.54% Beta-
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low136.74% ATR1.03
Employees46 Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)64.29 Volatility5.27% 7.87%
OptionableYes Debt/Eq0.18 EPS Q/Q-327.80% Profit Margin- Rel Volume0.66 Prev Close16.09
ShortableYes LT Debt/Eq0.18 EarningsFeb 04 AMC Payout- Avg Volume343.34K Price15.98
Recom- SMA2016.67% SMA5013.81% SMA200-10.17% Volume226,553 Change-0.68%
Dec-20-18 02:43PM  Should You Take Comfort From Insider Transactions At Evolus, Inc. (NASDAQ:EOLS)? Simply Wall St. -6.30%
Dec-19-18 08:01AM  Evolus Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-11-18 07:50AM  Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group Discovering Underlying Factors of Influence GlobeNewswire -5.18%
Dec-03-18 09:25AM  ALPHAEON repays outstanding principal amount under its secured convertible notes due December 23, 2018 PR Newswire
Nov-19-18 05:30AM  Evolus Receives Conditional FDA Acceptance of Jeuveau Brand Name GlobeNewswire -6.36%
Nov-05-18 04:05PM  Evolus Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 08:01AM  Evolus to Participate in Two Upcoming Investor Conferences GlobeNewswire
Oct-22-18 04:01PM  Evolus Expands Leadership Team with Appointments of Key Executives GlobeNewswire
08:10AM  Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare, and Frontline What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-19-18 03:02PM  What Kind Of Shareholder Owns Most Evolus Inc (NASDAQ:EOLS) Stock? Simply Wall St.
Oct-18-18 08:01AM  Evolus to Release Third Quarter 2018 Financial Results on Monday, November 5, 2018 GlobeNewswire
Sep-20-18 04:01PM  Evolus to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-05-18 08:01AM  Evolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury GlobeNewswire
Aug-29-18 08:01AM  Evolus Receives Acceptance of FDA BLA Resubmission for DWP-450 GlobeNewswire +17.65%
08:00AM  Maker of Botox Rival Soars as Treatment May Win Approval By Spring Bloomberg
Aug-17-18 08:01AM  Evolus Granted Approval of DWP-450 by Health Canada GlobeNewswire +5.22%
Aug-15-18 08:05AM  Evolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D GlobeNewswire
08:01AM  Evolus, Inc. Announces Full Exercise and Closing of Underwriters Overallotment Option GlobeNewswire
Aug-02-18 07:30AM  Evolus Reports Second Quarter 2018 Financial Results GlobeNewswire
07:25AM  Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450 GlobeNewswire
Jul-26-18 04:01PM  Evolus to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018 GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE
Jul-19-18 09:14AM  Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut Benzinga -7.36%
Jul-18-18 10:20PM  Evolus, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga -11.14%
Jul-16-18 04:01PM  Evolus, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-03-18 01:45PM  6 IPOs Bringing Rich Profits To Stock Investors Investopedia -6.27%
Jun-22-18 09:33AM  Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018 GlobeNewswire
Jun-18-18 08:01AM  Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer GlobeNewswire
Jun-14-18 08:01AM  Evolus to Participate in Two Upcoming Investor Conferences GlobeNewswire
Jun-08-18 04:45PM  Why Nabors Industries, PolarityTE, and Evolus Slumped Today Motley Fool -17.46%
Jun-04-18 08:01AM  Evolus to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire +11.77%
May-29-18 07:30AM  Evolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development GlobeNewswire +16.76%
May-24-18 02:36PM  Rival to Botox Roars Back With 123% Rally Despite FDA Delay Bloomberg +22.93%
May-16-18 02:27PM  Evolus investors frown as FDA declines to approve Botox rival Reuters -26.96%
12:56PM  INVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer Business Wire
11:13AM  Why Evolus, Inc. Is Crashing Today Motley Fool
11:07AM  Evolus investors frown as FDA declines to approve Botox rival Reuters
09:05AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:43AM  FDA declines to approve Evolus Inc's rival treatment to Botox Reuters
08:29AM  Evolus Announces Progress with DWP-450 Regulatory Submissions GlobeNewswire
07:01AM  Evolus to Provide Regulatory Update on Wednesday, May 16, 2018 GlobeNewswire
May-15-18 08:44AM  Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway Benzinga +6.78%
May-10-18 04:01PM  Evolus Reports First Quarter 2018 Financial Results GlobeNewswire +9.00%
May-07-18 07:01AM  Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer GlobeNewswire +20.19%
May-03-18 08:01AM  Evolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
Apr-23-18 07:30AM  Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS The Aesthetic Meeting GlobeNewswire
Apr-05-18 07:30AM  Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint GlobeNewswire -9.79%
Mar-29-18 07:30AM  Evolus Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire +8.27%
Feb-28-18 04:59PM  Who Really Owns Evolus Inc (NASDAQ:EOLS)? Simply Wall St. +5.50%
Feb-22-18 11:20AM  Evolus, Inc. (Nasdaq: EOLS) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-17-18 03:00PM  Evolus Announces Presentation of Phase III European - Canadian Comparative Data PR Newswire
Feb-16-18 12:31PM  Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA PR Newswire
Feb-12-18 11:05AM  Evolus, Inc. Announces Closing of Initial Public Offering of Common Stock PR Newswire
Feb-09-18 03:21PM  U.S. stock market chill threatens to 'put IPOs on ice' Reuters
Feb-08-18 09:42AM  U.S. IPOs start scraping through despite market jitters Reuters
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.